Intraoperative Fluorescence-Guided Resection of High-Grade Malignant Gliomas Using 5-Aminolevulinic Acid-Induced Porphyrins: A Systematic Review and Meta-Analysis of Prospective Studies

Shiguang Zhao1,2,*, Jianing Wu1,2,*, Chunlei Wang1,2, Hualei Liu1,2, Xingli Dong3, Chen Shi4, Changbin Shi5, Yaohua Liu1,2, Lei Teng1,2, Dayong Han1,2, Xiaofeng Chen1,2, Guang Yang1,2, Ligang Wang1,2, Chen Shen1,2, Huadong Li1,2

1 Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China, 2 Brain Science Institute of Harbin Medical University, Harbin, China, 3 Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, China, 4 Department of Neurosurgery, New York University Langone Medical Center and School of Medicine, New York, New York, United States of America, 5 Section of Neurosurgery, Department of Surgery, The University of Chicago Medical Center and Pritzker School of Medicine, Chicago, Illinois, United States of America

Abstract

Background: We performed a systematic review and meta-analysis to address the (added) value of intraoperative 5-aminolevulinic acid (5-ALA)-guided resection of high-grade malignant gliomas compared with conventional neuronavigation-guided resection, with respect to diagnostic accuracy, extent of tumor resection, safety, and survival.

Methods and Findings: An electronic database search of Medline, Embase, and the Cochrane Library was undertaken. The review process followed the guidelines of the Cochrane Collaboration. 10 studies matched all selection criteria, and were thus used for qualitative synthesis. 5-ALA-guided resection demonstrated an overall sensitivity of 0.87 (95% confidence interval [CI], 0.81–0.92), specificity of 0.89 (95% CI, 0.79–0.94), positive likelihood ratio (LR) of 7.62 (95% CI, 3.87–15.01), negative LR of 0.14 (95% CI, 0.09–0.23), and diagnostic odds ratio (OR) of 53.06 (95% CI, 18.70–150.51). Summary receiver operating characteristic curves (SROC) showed an area under curve (AUC) of 94%. Contrast-enhancing tumor was thus used for qualitative synthesis. 5-ALA-guided resection demonstrated an overall sensitivity of 0.87 (95% confidence interval [CI], 0.81–0.92), specificity of 0.89 (95% CI, 0.79–0.94), positive likelihood ratio (LR) of 7.62 (95% CI, 3.87–15.01), negative LR of 0.14 (95% CI, 0.09–0.23), and diagnostic odds ratio (OR) of 53.06 (95% CI, 18.70–150.51). Summary receiver operating characteristic curves (SROC) showed an area under curve (AUC) of 94%. Contrast-enhancing tumor was completely resected in patients assigned 5-ALA as compared with patients assigned white light. Patients in the 5-ALA group had higher 6-month progression free survival and overall survival than those in the white light group.

Conclusion: Based on available literature, there is level 2 evidence that 5-ALA-guided surgery is more effective than conventional neuronavigation-guided surgery in increasing diagnostic accuracy and extent of tumor resection, enhancing quality of life, or prolonging survival in patients with high-grade malignant gliomas.

Introduction

Malignant gliomas are locally invasive brain tumors which inevitably lead to death within two years after diagnosis [1,2]. The first reported case of glioma resection was performed by Rickman Godlee in 1884 [3]. As far as surgery is concerned, resection of the main tumor mass to achieve debulking in symptomatic patients is a widely accepted strategy [4]. Extent of tumor resection (EOTR) is increasingly accepted as critical to optimal surgical treatment and patient outcome [1,5]. Since malignant gliomas do not have a distinct margin between the tumor mass and the surrounding brain, achieving gross total tumor resection represents a major challenge to the neurosurgeon. Numerous surgical technologies have been developed to facilitate optimal resection, many of which function to guide the surgeon during resection. These technologies include intraoperative magnetic resonance imaging (MRI), intraoperative ultra-sound, intraoperative computed tomography (CT), and fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA).

The implementation of 5-ALA-guided surgery is considered to be much simpler and less costly than other types of surgery for patients with malignant glioma [6]. 5-ALA is a precursor in the hemoglobin synthesis pathway which elicits the synthesis and accumulation of fluorescent porphyrins in various epithelia and cancerous tissues [7]. Oral administration of 5-ALA several hours before surgery leads to the preferential accumulation of protoporphyrins.
Phyryin IX (PpIX) within glioma cells. Under blue-violet light conditions, the PpIX emits light in the red region of the visible spectrum, enabling identification of tumor tissue that would otherwise be difficult to distinguish from normal brain [8–10]. A large, multicentre phase III randomised control trial comparing 5-ALA-induced fluorescence-guided surgery with conventional white light surgery for malignant glioma was a landmark in fluorescence-guided surgical resection [11,12]. 5-ALA guided resection of primary malignant brain tumors was found to be beneficial, resulting in a significantly higher resection rate, which translated into a longer progression-free interval, as well as a longer median survival time.

Since the introduction of 5-ALA, many studies have reported on the (added) value of 5-ALA-guided surgery. However, to the best of our knowledge, no systematic review and meta-analysis on this topic has been published. 5-ALA has been approved for intracranial use in Europe, Canada, and Japan, but not in the United States [8]. Widespread use of 5-ALA should be based on evidence.

We did a systematic review and meta-analysis of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [13]. Our objective was to address the (added) value of 5-ALA-induced fluorescence-guided resection of high-grade malignant gliomas particularly glioblastoma multiforme (GBM), compared with conventional neuronavigation-guided resection, with respect to diagnostic accuracy, EOTR, safety, and survival.

### Methods

#### Research Protocol

Our research protocol consisted of the detailed research question, search strategy, screening criteria for titles, abstracts, and full-text articles. The detailed research question was formed by the patient, intervention, comparator, outcome, study design (PICOS) approach. Our objective was to address the (added) value of 5-ALA-induced fluorescence-guided resection of high-grade malignant gliomas particularly GBM compared with conventional neuronavigation-guided resection, with respect to diagnostic accuracy, EOTR, safety, and survival.

We considered only the two most reliable types of studies. These were prospective studies on diagnostic accuracy and therapeutic outcome. Only trials designed for level 1 and 2 were included (Level 1: High quality randomized trial or prospective study; Level 2: Lesser quality RCT; prospective comparative study). Diagnostic accuracy was investigated by examining tissue biopsy samples surgically excised by 5-ALA-induced fluorescence-guided surgery in combination with conventional neuronavigation-guided surgery. Patients had to have a suspected or proven high-grade malignant gliomas. EOTR, safety, and survival were assessed after

![Flow diagram outlining the study selection process.](doi:10.1371/journal.pone.0063682.g001)
randomising patients under-going resection with either white light (WL) alone or combining with 5-ALA. Both procedures were only considered in primary gliomas. A lesion-based measure was preferred over a patient-based one for clinical relevance.

Search databases were Medline (using PubMed), Embase (using Ovid), and the Cochrane Library. Search queries were optimised for each specific database.

Titles and abstracts were screened and included if they represented randomised or cohort studies of patients with high-grade malignant gliomas who received neurosurgical intervention using 5-ALA. Duplicate records were deleted. Studies that specifically reported on a pediatric population or focused on chemotherapy or radiosurgery, radiotherapy were excluded. Studies in abstract form, case reports, and a language other than English were excluded. Studies including fewer than 20 patients or 100 biopsies were not retained. Of the remaining records, full-text articles were assessed according to the same criteria, with one additional exclusion criterion (overlapping data). Shiguang Zhao and Jianing Wu set up the research protocol, and searches were done independently by Huailei Liu and Chunlei Wang. Xingli Dong served as an independent third reviewer in cases where opinion differed between the two reviewers.

Eligibility Criteria and Search Strategy

The PICOS research question was a foundation for study selection. An electronic database search of Medline, Embase, and the Cochrane Library was undertaken. Since 5-ALA is a

Table 1. Exclusion of clinical trials and reasons for exclusion.

| Publication               | Reason for exclusion                           |
|---------------------------|------------------------------------------------|
| Ewelt et al. [22]         | Low-grade gliomas                              |
| Valdes et al. [27]        | Primary endpoint is quantitative ex vivo tissue measurements of PpIX |
| Utsuki et al. [28]        | Retrospective study                            |
| Tsugut et al. [29]        | Retrospective study                            |
| Stummer et al. [30]       | Primary endpoint is the influence of the degree of resection on survival |
| Schucht et al. [31]       | Retrospective study                            |
| Nabavi et al. [32]        | Recurrent malignant glioma study               |
| Panciani et al. [33]      | Overlapping data with Panciani et al. [19]     |
| Idoate et al. [34]        | Overlapping data with Diez Valle et al. [23]   |
| Floeth et al. [35]        | Low-grade gliomas                              |
| Pichlmayer et al. [36]    | Overlapping data with Stummer et al. [9]       |
| Stepp et al. [37]         | Overlapping data with Stummer et al. [9]       |

doi:10.1371/journal.pone.0063682.t001
### Table 2. Study design parameters of studies included.

| Publication          | Study Type   | Mean (range) age (years) | Inclusion criteria                      | Exclusion criteria                          | Recruitment Time                                   | Primary endpoint                          | Measurement of primary endpoint |
|----------------------|--------------|--------------------------|-----------------------------------------|--------------------------------------------|---------------------------------------------------|------------------------------------------|----------------------------------|
| Panciani et al.      | Prospective study | (43–79)                   | GBM                                     | Eloquent areas. More than one contrast-enhancing lesion. | Nov. 2008 to Mar. 2010                            | Diagnostic accuracy                      | Neuropathology                   |
| Stummer et al.       | RCT          | 61.0 (23–73)              | WHO Grade III/IV glioma                 | NS                                        | EOTR, safety, survival                            | CE on EPMRI, KPS, NIH-SS score, event-free survival rate |
| Stummer et al.       | Prospective Study | 60.7 (21–80)             | WHO Grade III/IV glioma                 | Conditions prohibiting the administration of 5-ALA | Jan. 10, 2005 to Nov. 26, 2007.                   | Safety, and survival                     | Adverse event, KPS, overall survival rate |
| Roberts et al.       | Prospective Study | 63.8 (52–80)             | GBM                                     | Conditions prohibiting the administration of 5-ALA | Aug. 2008 and Apr. 2009                           | Diagnostic accuracy                      | Neuropathology                   |
| Diaz Valles et al.   | Prospective Study | 58.4 (30–73)             | GBM                                     | Bilateral tumor, multiple distant lesions  | Oct. 2007 to Jun. 2009                            | Diagnostic accuracy, EOTR, safety, survival | Neuropathology, CE on EPMRI, adverse event, PFS, overall survival |
| Eljamel et al.       | Prospective Study | NS                       | NS                                      | NS                                        | NS                                                | Diagnostic accuracy                      | Neuropathology                   |
| Hefti et al.         | Prospective Study | NS                       | Malignant glioma                        | NS                                        | May 2006 to May 2007                              | Diagnostic accuracy                      | Neuropathology                   |
| Eljamel et al.       | RCT          | 59.6                      | GBM                                     | Whose diagnosis was not GBM                | NS                                                | Safety, survival                         | Adverse event, KPS, estimated survival |
| Stummer et al.       | RCT          | 60 (23–73)                | WHO Grade III/IV glioma                 | Low-grade glioma                            | Oct. 11, 1999 to Jul.19, 2004                     | EOTR, survival                           | CE on EPMRI, KPS, progression-free survival |
| Stummer et al.       | Prospective Study | 53.8 (31–69)             | GBM                                     | Conditions prohibiting the administration of 5-ALA | Dec. 1995 to Dec. 1998                            | Diagnostic accuracy, EOTR, survival       | Neuropathology, CE on EPMRI, time from surgery to death |

Abbreviations: RCT, randomised control trial; NS, not specified; EOTR, extent of tumor resection; GBM, glioblastoma multiforme; KPS, Karnofsky performance score; CE, contrast enhancement; EPMRI, early postoperative MRI; PFS, progression-free survival.
somewhat new technique, the topic itself limited the publication dates (last search was done Oct. 15th, 2012). We used PubMed as our primary data source, and searched the above databases using the following MeSH terms and search strategies:

- PubMed: Brain neoplasms; OR Protoporphyrins AND aminolevulinic acid; OR Photosensitizing agents.
- Cochrane Library: glioblastoma; OR Protoporphyrins; OR Aminolevulinic acid.
- Medline: Protoporphyrins AND diagnostic use; OR Photosensitizing agents.

The Ovid query with thesaurus terms was: #1 Protoporphyrins or aminolevulinic acid or protoporphyrin IX.mp. [mp = tx, bt, ti, ab, ct]; #2 (Brain neoplasms or glioma or glioblastoma).mp. [mp = tx, bt, ti, ab, ct]; #3 (#1 and #2).

The Cochrane Library query with keywords was: #1 (MeSH descriptor Brain neoplasms explode all trees); #2 (glioblastoma.kw OR (glioma):kw); #3 (#1 OR #2); #4 (Protoporphyrins):kw OR (Aminolevulinic acid):kw OR (protoporphyrin IX):kw; #5 (#3 AND #4).

Data Extraction and Quality Assessment

After screening the database search results, full-text assessment was done for study selection. The review process was performed according to the guidelines of the Cochrane Collaboration. All data were extracted into a computer-based spreadsheet. The authors, publication year, study type, and clinical data were included. In addition, the following clinical data were extracted for each diagnostic accuracy trial, where available: specificity, sensitivity, true-positive (TP), false-positive (FP), true-negative (TN), and false-negative (FN). If such information was not reported specifically in the original article, we performed an analysis with the reported data to generate desired values when possible. Diagnostic accuracy was assessed by sensitivity, specificity, positive likelihood ratio (LR), negative LR, and diagnostic odds ratio (OR). EOTR was assessed by comparing residual contrast-enhancing tumor volume. Safety was assessed by comparing adverse events (AEs), serious adverse events (SAEs), the NIH-SS score, and the KPS score. Survival was assessed by progression-free survival and overall survival time. The quality and applicability of studies were assessed using checklists of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS, scale 0–14). QUADAS is an evidence based tool to be used for the quality assessment of diagnostic accuracy studies in systematic reviews. It consists of 14 items phrased as questions, each of which should be scored a “yes”, “no” or “unclear” that examine bias in the study [14].

Statistical Analysis

All analyses were performed at the biopsy level. All samples were examined for histologic diagnosis according to the World Health Organization (WHO) classification of tumors of the central nervous system [15]. Primary data synthesis was performed within the bivariate mixed-effects binary regression modeling framework with Stata 11 (StataCorp). The bivariate fixed-effects regression model was employed for specificity analysis, and random-effects regression model for sensitivity analysis. In the fixed-effects regression model, the results of individual studies were pooled using weights that depended on the sample size of the study, whereas in the random-effects regression model, each study was weighted equally [16]. Average sensitivity, specificity, LR, OR, and 95% confidence interval (CI) were calculated from the maximum likelihood estimates, and graphically assessed by the summary receiver operating characteristic curves (SROC). Heterogeneity of the results between studies was assessed graphically

### Table 3. Prospective trials accepted for analysis.

| Publication                      | TRUE Positive (%) | FALSE Positive (%) | TRUE Negative (%) | FALSE Negative (%) | Sensitivity (95% CI) | Specificity (95% CI) | Positive LR (95% CI) | Negative LR (95% CI) | Diagnostic OR (95% CI) |
|----------------------------------|-------------------|--------------------|-------------------|-------------------|----------------------|----------------------|----------------------|----------------------|------------------------|
| Panciani et al. (2012)           | 41                | 5                  | 4                 | 42                | 0.91 (0.75–0.98)     | 0.90 (0.74–0.95)     | 8.62 (3.07–24.31)    | 0.10 (0.04–0.25)     | 86.10 (21.59–343.41)   |
| Roberts et al. (2011)            | 82                | 4                  | 28                | 10                | 0.75 (0.65–0.82)     | 0.92 (0.75–0.94)     | 42.0 (17.1–100.4)    | 0.36 (0.22–0.56)     | 7.32 (2.13–25.21)      |
| Diez Valle et al. (2011)         | 142               | 2                  | 12                | 24                | 0.87 (0.70–0.93)     | 0.95 (0.80–1.00)     | 11.99 (3.16–45.45)   | 0.03 (0.02–0.16)     | 14.21 (3.16–67.43)     |
| Hefti et al. (2008)              | 73                | 3                  | 11                | 26                | 0.89 (0.79–0.94)     | 0.90 (0.70–1.00)     | 24.04 (3.71–164.49)  | 0.08 (0.02–0.16)     | 37.61 (9.45–149.69)    |
| Stummer et al. (2000)            | 211               | 1                  | 26                | 26                | 0.87 (0.71–0.93)     | 0.89 (0.70–1.00)     | 24.04 (3.71–164.49)  | 0.14 (0.09–0.23)     | 53.06 (18.70–150.51)   |
| Combined                         | 41                | 4                  | 28                | 10                | 0.91 (0.75–0.98)     | 0.90 (0.74–0.95)     | 8.62 (3.07–24.31)    | 0.10 (0.04–0.25)     | 86.10 (21.59–343.41)   |

doi:10.1371/journal.pone.0063682.t003
on Forest plots and statistically using the $x^2$ test and Cochran Q. I-squared ($I^2$) described the percentage of total variation across studies due to heterogeneity rather than chance, and was also used as a measure to quantify the amount of heterogeneity. $I^2>50\%$ suggested heterogeneity [17]. Publication bias was assessed by a Funnel plot asymmetry test [18]. Statistics were performed with Stata 11 (StataCorp), and a $P$ value less than 0.05 was considered statistically significant.

**Results**

**Identification and Characteristics of Studies**

Our search identified 473 potentially relevant reports, of which 336 were retrieved for detailed evaluation (Figure 1). Totally, 322 reports including some clinical trials were excluded for the reasons given in Figure 1 and Table 1. A total of 14 study reports met the inclusion criteria, including 4 reports from the same study. The remaining 10 articles were used for quantitative synthesis [4,11,12,19–21,23–26], including seven prospective and three randomised controlled trials (RCT). Studies where the prospective or retrospective design was not specified in the full-text article were assessed independently by both reviewers, who agreed in all cases. Publication years were between 2000 and 2012. Most studies gave inclusion and exclusion criteria for patient selection. Six studies included data on diagnostic accuracy of GBM [4,19,21,23,24,26]. Five of these articles published biopsy-based detection rates, and thus included in our meta-analysis [4,19,21,23,26]. Survival data were available in six of 10 studies [11,12,20,23,24,26]. Four articles were published by the ALA-Glioma study group [11,12,20,26]. Detailed study design parameters for the selected studies are shown in Table 2. Table 3 shows the data of studies on diagnostic accuracy of GBM. Results of distribution of study design characteristics in six diagnostic studies according to QUADAS items are shown in Figure 2.

**Diagnostic Accuracy**

Six studies [4,19,21,23,24,26] reported the data on diagnostic accuracy of GBM with 5-ALA, five of which were lesion-based [4,19,21,23,26]. The patient-based study did not report data that could be used to construct or calculate TP, FP, TN and FN results [24]. Five articles were selected for data extraction and data analysis. Seven hundred and sixty-four brain lesions were included from the five studies. Figure 3 shows the sensitivity and specificity of included studies, stratified by the reference standard. 5-ALA demonstrated an overall sensitivity of 0.87 (95% CI, 0.81–0.92), specificity of 0.89 (95% CI, 0.79–0.94). A homogeneity test of sensitivity and specificity showed $Q=20.82$ ($P<0.001$), $I^2=80.78\%$ and $Q=6.25$ ($P=0.18$), $I^2=36.02\%$, respectively. Therefore, notable heterogeneity was detected in the sensitivity analysis. The Positive LR was 7.62 (95% CI, 3.87–15.01), Negative LR was 0.14 (95% CI, 0.09–0.23), and Diagnostic OR was 53.06 (95% CI, 18.70–150.51). The SROC for the diagnosis of GBM versus non brain
tumor lesion is presented in Figure 4. The area under the curve of SROC was 0.94.

Two of these studies investigated diagnostic accuracy by examining tissue biopsy samples surgically excised by 5-ALA-induced fluorescence-guided surgery in combination with conventional neuronavigation-guided surgery [4,19]. These studies demonstrated the ability of 5-ALA to detect more tumor lesions when compared to conventional neuronavigation-guided surgery (Table 4).

Different fluorescent qualities were observed in GBM patients [4,21,23,26]. Stummer et al. [26] and Hefti et al. [4] showed that viable tumor tissue could be identified by its deep red fluorescence, which they called “solid”, whereas normal brain tissue was colored blue. They also reported a pink fluorescence which was encountered between solidly fluorescing tumor and non-fluorescing blue brain tissue, and they called this kind of fluorescence “vague”. Diez et al. [23] also differentiated different fluorescent qualities, with neat distinction of the solid mass of the tumor in bright red, and the border in shades of pink. Roberts et al. [21] assigned biopsy sites a fluorescence level consisting of 0, no fluorescence; 1, low fluorescence; 2, moderate fluorescence; or 3, high fluorescence. Two studies calculated sensitivity and specificity according to strong fluorescence and vague fluorescence respectively (Table 5).

Assessment of EOTR

Four studies assessed EOTR, which was measured by early postoperative MRI [11,12,23,26]. These studies described how the use of 5-ALA affected EOTR and helped in achieving gross total resection. Three studies were conducted by the ALA-Glioma study group [11,12,26]. The study conducted by Stummer et al. in 2011 [12] was a supplemental analysis to a randomised controlled multicentre phase III trial completed by the same group [11].

Stummer et al. [26] prospectively reported that on postoperative MR images, complete resection of contrast-enhancing tumor was observed in 33 (63%) of 52 patients. Areas of residual contrast enhancement were identified by comparing T1-weighted non-contrast-enhanced and contrast-enhanced axial sections (matrix 256×256 pixels, 5-mm slices, 1-mm gap; 0.1 mmol gadolinium-diethylenetriamine pentaacetic acid/kg body weight). Of 17 patients in whom complete removal of fluorescent tissue was achieved, 16 revealed no residual enhancement on postoperative MR images. In the remaining patient, a small region of residual enhancement was found. On the other hand, postoperative MR imaging was also devoid of residual enhancement in nine of 12 patients with vague residual fluorescence but in only eight of 23 patients with solid residual fluorescence.

A randomised controlled multicentre phase III trial conducted by Stummer et al. reported that contrast-enhancing tumor was completely resected in 90 (65%) of 139 patients assigned 5-ALA compared with 47 (36%) of 131 assigned white light (P<0.0001) [11]. Stummer et al. subsequently reported that the percentage of patients without residual tumor on early postoperative MR imaging in the ALA group was 63.6%, and it was 37.6% in the WL group (P<0.0001) [12]. More frequent complete resections were confirmed, with higher median residual tumor volumes in the WL group (0.5 vs 0 cm³, P=0.001). Residual tumor was defined as contrast enhancement with a volume >0.175 cm³ in both studies. Diez et al. [23] reported that all the contrast-enhancing volume was resected in 83.3% of the patients, all patients had resection over 98% of the volume and mean volume resected was 99.8%.

Safety and Survival

Safety regarding neurological function was assessed in four studies by recording AEs, SAEs, the NIH-S5 score, and the KPS score [12,20,23,25]. In a multicentric phase II safety study of 5-ALA, 6-week AE incidence in 243 patients evaluable for safety, was 51.9% (nervous system disorders: 30.0%) [20]. Stummer et al. [12] reported that the incidence of AEs (excluding SAEs) was 58.7% in the ALA group and 57.8% in the WL group, as was the incidence in the subgroup of neurological AEs (P=0.74).

Survival data were available in six studies [11,12,20,23,25,26], three of which were RCT [11,12,23]. Progression-free survival and overall survival in these three studies are shown in Table 6. Patients in 5-ALA group had higher 6-month progression free survival and overall survival than those in white light group.

Discussion

To our knowledge, this is the first systematic review to address the (added) value of 5-ALA-guided resection of high-grade malignant gliomas compared with conventional neuronavigation-guided surgery, with respect to diagnostic accuracy, EOTR, safety, and survival. Only trials designed for level 1 and 2 were included. Meta-analysis of data was possible and indicated that 5-ALA-guided surgery can additionally detect residual tumors in patients

Table 4. Detection of tumor lesions in comparison of the administration of 5-ALA with conventional neuronavigation.

| Publication                      | 5-ALA sensitivity | Neuronavigation sensitivity | 5-ALA specificity | Neuronavigation specificity |
|----------------------------------|------------------|-----------------------------|------------------|-----------------------------|
| Panciani et al. (2012)           | 91.1%            | 57.4%                       | 89.4%            | 57.4%                       |
| Hefiti et al. (2008)             | 87.0%            | 66.0%                       | 85.0%            | 68.0%                       |

doi:10.1371/journal.pone.0063682.t004
with high-grade malignant gliomas. Our estimate of the incremental accuracy of 5-ALA, using SROC curves, showed an AUC of 94%. Evidence from these studies also showed 5-ALA-guided surgery enable more complete resections of contrast-enhancing tumor, leading to improved progression-free survival in patients with high-grade malignant glioma. Although 5-ALA allows the neurosurgeon to more accurately distinguish glioma margins intraoperatively, many studies published on 5-ALA-guided resection of glioma have some important limitations.

## Low Sensitivity in Low-grade Gliomas

Different types of gliomas differ substantially in macroscopic and sometimes MRI appearance, and in survival. Our review focused on high-grade gliomas in general, and GBM in particular. Evidence showed that the high specificity and sensitivity of 5-ALA-induced PpIX fluorescence in high-grade gliomas allowed immediate and reliable identification of these tumors. However, visible 5-ALA induced fluorescence is rare in low grade glioma (WHO I and II). Therefore, lower grade glioma cannot be reliably resected by fluorescence-assisted surgery alone. In these cases, the additional use of intraoperatively imaging-based neuronavigational methods (MR, ultrasound) may be required.

## Fluorescent Quality

Many studies reported different qualities of fluorescence induced by 5-ALA were observed in brain tissues, and visible levels of fluorescence correlated with tumor burden and WHO grades [4,21,23,26]. Two types of fluorescence were noted: solid fluorescence and vague fluorescence. Sometimes, the assessment of intraoperative 5-ALA-induced fluorescence by surgeon was largely subjective. This approach is limited in its sensitivity for identifying low levels of fluorescence in tumor, potentially leaving some amount of resectable tumor unidentified [27]. There are two approaches to overcome this limitation. One is quantitative or semi-quantitative measurement of fluorescence intensity during operation, and the other is to enhance PpIX fluorescent quality.

Valdes et al. [27] conducted quantitative ex vivo measurement of PpIX concentration with proliferation index and glioma grades on histopathology, and showed that ex vivo quantitative measurement of PpIX concentration in tissue is more sensitive at identifying both low- and high-grade gliomas than current intraoperative fluorescence imaging. As a result, there remains a critical need to improve intraoperative PpIX fluorescence detection to achieve better sensitivity in determination of brain tumor, subsequently leading to optimal surgical resection. Our group also tried to find an approach to enhance PpIX fluorescent quality for optimising the subjective discrimination of vague fluorescence and improving the effect of 5-ALA [38,39].

### Assessment of EOTR

A growing body of evidence demonstrated that a more extensive surgical resection could improve outcomes of patients with malignant gliomas [1,30,40,41]. Fluorescence-guided resection could offer real time viewing of the tumor in the operative field, and this should allow neurosurgeon to resect almost all the tumoral tissue in most cases. The main approach used to assess EOTR is to examine early postoperative contrast enhancement on T1-weighted MRI. This approach is a rough method that dichotomises gross total resection assessment to yes or no [6]. The MacDonald criteria [42], Response Assessment in Neuro-Oncology criteria (RANO) [43], and Response Evaluation Criteria In Solid Tumors (RECIST) [44] are not useful for postoperative assessment of tumor size because they require spherical tumor. It is clear that contrast enhancement at the border of the resection cavity is not the case [6]. Consequently, more reliable and valid criteria to assess EOTR are necessary for neurosurgical studies.

### Future Research

Based on the results of this systematic review, we have a few recommendations for future studies on 5-ALA-guided resection of gliomas. First, as mentioned previously, widespread use of 5-ALA should be based on evidence. The safety and efficacy of 5-ALA-guided resection of gliomas depend on the better understanding of its underlying mechanisms. Second, the intraoperative fluorescence needs to be quantified and the correlation between

| Publication               | No. of patients | Subgroup | Overall survival (mo) | PFS rate at 6 months |
|---------------------------|-----------------|----------|-----------------------|----------------------|
|                           |                 |          | 5-ALA | WL | 5-ALA | WL |
| Stummer et al. (2011)     | 349             | –        | 14.3 | 13.7 | 46.0% | 28.3% |
| Eljamel et al. (2008)     | 27              | –        | 12.3 | 5.6  | –     | –     |
| Stummer et al. (2006)     | 270             | older    | 14.1 | 11.5 | 41.0% | 21.1% |
|                           |                 | younger  | 18.0 | 17.5 |       |       |

Abbreviations: Mo, month; PFS, progression-free survival; WL, white light.

| Table 5. Calculated sensitivity and specificity for strong fluorescence and vague fluorescence. |
|---------------------------------------------------------------|
| Publication                  | Strong fluorescence (bright red) | Vague fluorescence (pink) |
|                              | sensitivity | specificity | sensitivity | specificity |
| Diez Valle et al. (2011)     | 85.7%       | 100.0%      | 85.4%       | 92.3%       |
| Hefti et al. (2008)          | 98.0%       | 100.0%      | 76.0%       | 85.0%       |

References:

1. Diez Valle, C., et al. (2011).
2. Hefti, F., et al. (2008).
3. Stummer, C., et al. (2011).
4. Eljamel, M., et al. (2008).
5. Stummer, C., et al. (2006).
6. MacDonald, M., et al. (2004).
7. Response Assessment in Neuro-Oncology criteria (RANO) (2009).
8. Response Evaluation Criteria In Solid Tumors (RECIST) (2009).

PLOS ONE | www.plosone.org 8 May 2013 | Volume 8 | Issue 5 | e63682
fluorescence and its histopathology needs to be further investigated. Third, in this review certain studies could not be used for meta-analysis because some statistical analyses were not available in their studies. In addition, the numbers of trials in meta-analysis were too small to analyze publication bias. A well-designed meta-analysis is essential for the assessment of EOTR, safety, and survival may differ across studies. No meta-analysis was planned about the assessment of EOTR, safety, and survival, because we did not expect that a valid quantitative data synthesis could be done. There is an obvious need for standardization of the assay procedure and the assessment of the specimens as well as for the initiation of a prospective multi-centre trial to provide definite answers. In this context, higher quality of studies on 5-ALA are necessary to show its added value as compared with standard treatment.

Conclusion

Based on available literature, there is currently, at best, level 2 evidence that 5-ALA-guided surgery is more effective than conventional neuronavigation-guided surgery in increasing diagnostic accuracy and EOTR, enhancing quality of life, or prolonging survival in patients with high-grade malignant glioma.

Supporting Information

Appendix S1 PRISMA Checklist. (DOC)

Author Contributions

Conceived and designed the experiments: SGZ JNW. Performed the experiments: CJN HIL XLD. Analyzed the data: XLD YHL DYH C. Shen HDL. Contributed reagents/materials/analysis tools: XFC GY LGW C. Shi CBS LT. Wrote the paper: XLD JNW XLW.

References

1. Lacroix M, Abi-Said D, Fourney DR, Goksalan ZL, Shi W, et al. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognostic extent of resection and survival. J Neurosurg 95: 190–198.
2. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, et al. (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375–1382.
3. Bennett H, Goldie RJ (1984) Excision of a tumour from the brain. Lancet 2: 1090–1091.
4. Hefi M, von Campe G, Mochepulos M, Siegner A, Looser H, et al. (2008) 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institution. Swiss Med Wkly 138: 180–183.
5. M-Giunti MJ, Chiaichiana KL, Gathini M, Attellенно FJ, Thak K, et al. (2009) Independent association of extent of resection with survival in patients with malignant brain astro-cytoma. J Neurosurg 110: 156–162.
6. Kubben PL, ter Meulen KJ, Schijns OE, ter Laak Poort MP, van Overbeeke JJ, et al. (2011) Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 12: 1062–1070.
7. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, et al. (1995) Photossensitisation and photodynamic therapy of oesophageal, thyroidal, and colorectal tumours using 5-aminolevulinic acid induced protoporphyrin IX—a pilot study. Gut 36: 67–75.
8. Roberts DW, Valdes PA, Harris BT, Hartov A, Fan X, et al. (2012) Glioblastoma multiforme treatment with clinical trials for surgical resection of glioblastoma multiforme. Neurosurg Clin N Am 23: 371–377.
9. Stummer W, Stepp H, Muller G, Ehrhardt A, Leonard M, et al. (1998) Technical principles for protoporphyrin IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir 140: 995–1000.
10. Duffner F, Ritz R, Freudenstein D, Weller M, Dietz K, et al. (2005) Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neurosurg 71: 107–111.
11. Stummer W, Pinchmeier U, Meinelt T, Wieseler OD, Zanella F, et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392–401.
12. Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, et al. (2011) Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg 114: 613–623.
13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
14. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25.
15. Louis DN, Ohtaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.
16. Walker E, Hernandez AV, Kattan MW (2008) Meta-analysis: Its strengths and limitations. Cleve Clin J Med 75: 431–439.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
18. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
19. Pancioli PP, Fontanella M, Schiafio B, Garbossa D, Agugliaro A, et al. (2012) Fluorescence and image guided resection in high grade glioma. Clin Neurol Neurosurg 114: 37–41.
20. Stummer W, Nestler U, Stockhammer F, Kress D, Kern BC, et al. (2011) Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 103: 361–370.
21. Roberts DW, Valdes PA, Harris BT, Fontaine KM, Harton A, et al. (2011) Coregistered fluorescence-enhanced tumor resection of malignant gliomas: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J Neurosurg 114: 595–603.
22. Everlt G, Floeth VW, Felberg J, Steiger HJ, Sahel M, et al. (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113: 541–547.
23. Diez Valle R, Tejada Solis I, Isidre Gastrarena MA, Garcia de Eulate R, Dominguez Echavarri P, et al. (2011) Surgery guided by 5-aminolevulinic acid fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurosurg 102: 105–113.
24. Eljamal MS (2009) Which intracranial lesions would be suitable for 5-aminolevulinic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. Clin Neurosci 56: 93–97.
25. Eljamal MS, Goodman C, Moseley H (2000) ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomized controlled trial. Lasers Med Sci 23: 361–367.
26. Stummer W, Novotny A, Stepp H, Goetz C, Bie K, et al. (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93: 1005–13.
27. Valdes PA, Kim A, Brantsch M, Niu C, Moses ZB, et al. (2011) delta-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol 13: 846–856.
28. Utsuki S, Oka H, Sato S, Shimizu S, Suzuki S, et al. (2007) Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo) 47: 210–213; discussion 213–214.
29. Tsuji A, Ishizaka H, Mizokami Y, Osada T, Baba T, et al. (2011) Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma. World Neurosurg 76: 120–127.
30. Stummer W, Reulen HJ, Meinelt T, Pichleinie U, Schumacher W, et al. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62: 564–576; discussion 564–576.
31. Schuch P, Beck J, Abe-Isa J, Andereggen L, Murck M, et al. (2012) Gross Total Resection Rates in Contemporary Glioblastoma Surgery: Results of an
Institutional Protocol Combining 5-ALA Intraoperative Fluorescence Imaging and Brain Mapping. Neurosurgery 71: 927–936.

32. Nabavi A, Thurm H, Zountas B, Pletsch T, Lanfermann H, et al. (2009) Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 65: 1070–1076; discussion 1076–1077.

33. Panciani PP, Fontanella M, Garbossa D, Agnoletti A, Ducati A, et al. (2012) 5-aminolevulinic acid and neuronavigation in high-grade glioma surgery: results of a combined approach. Neurocirugía (Astur) 23: 23–28.

34. Idoate MA, Díez Valle R, Echeveste J, Tejada S (2011) Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 31: 575–582.

35. Floeth FW, Sabel M, Eroch G, Stummer W, Felsberg J, et al. (2011) Comparison of [18]F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging 38: 731–741.

36. Pichlmeier U, Bink A, Schackert G, Stummer W (2008) Resection and survival in glioblastoma multiforme: an RT0G recursive partitioning analysis of ALA study patients. Neuro Oncol 10: 1025–1035.

37. Stepp H, Beck T, Pongratz T, Meinel T, Kreth FW, et al. (2007) ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 26: 157–164.

38. Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, et al. (2011) Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 104: 798–807.

39. Zhao SG, Chen XF, Wang LG, Yang G, Han DY, et al. (2012) Increased Expression of ABCB6 Enhances Protoporphyrin IX Accumulation and Photodynamic Effect in Human Glioma. Ann Surg Oncol. In press.

40. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45–61.

41. Sanai N, Berger MS. (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 733–764; discussion 264–266.

42. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280.

43. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro- oncology working group. J Clin Oncol 28: 1963–1972.

44. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216.